Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M, Lamoureux A, Meunier L, Samaran Q, Lesage C, Girard C, Du Thanh A, Moulis L, Dereure O. Fabre M, et al. Among authors: lesage c. Melanoma Res. 2024 Jun 1;34(3):241-247. doi: 10.1097/CMR.0000000000000963. Epub 2024 Mar 28. Melanoma Res. 2024. PMID: 38546723
[Post-traumatic acral melanoma: an underestimated reality?].
Lesage C, Journet-Tollhupp J, Bernard P, Grange F. Lesage C, et al. Ann Dermatol Venereol. 2012 Nov;139(11):727-31. doi: 10.1016/j.annder.2012.06.034. Epub 2012 Aug 30. Ann Dermatol Venereol. 2012. PMID: 23199769 Review. French.
[Innovative therapies for metastatic melanoma in elderly patients].
Du-Thanh A, Lesage C, Ferreira E, Dereure O, Guillot B. Du-Thanh A, et al. Among authors: lesage c. Ann Dermatol Venereol. 2015 Oct;142(10):549-56. doi: 10.1016/j.annder.2015.03.022. Epub 2015 May 16. Ann Dermatol Venereol. 2015. PMID: 25986740 Review. French.
Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B; French Group of Onco-Dermatology. Lesage C, et al. Among authors: lesage fx. J Immunother. 2019 Jun;42(5):175-179. doi: 10.1097/CJI.0000000000000268. J Immunother. 2019. PMID: 31090656
Myasthenia Gravis Induced by Immune Checkpoint Inhibitors.
Becquart O, Lacotte J, Malissart P, Nadal J, Lesage C, Guillot B, Du Thanh A. Becquart O, et al. Among authors: lesage c. J Immunother. 2019 Oct;42(8):309-312. doi: 10.1097/CJI.0000000000000278. J Immunother. 2019. PMID: 31246640 Review.
[Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania].
Rivet V, Quantin X, Faillie JL, Lesage C, Meunier L, Faure S, Hillaire-Buys D, Lesouder C, Fabre S, Assenat E, Rullier P, Guilpain P, Maria ATJ. Rivet V, et al. Among authors: lesage c. Rev Med Interne. 2021 May;42(5):310-319. doi: 10.1016/j.revmed.2021.01.002. Epub 2021 Jan 21. Rev Med Interne. 2021. PMID: 33485701 French.
Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.
Connell E, Gerard É, Oules B, Brunet-Possenti F, Lamoureux A, Bonnefille H, Mary-Prey S, Carrasquilla A, Mouret S, Kramkimel N, Lesage C, Stoebner PE, Bartoli A, Monestier S, Correard F, Gros A, Jeanson A, Ouafik L, Gaudy-Marqueste C, Tomasini P, Charles J, Amini-Adle M, Malissen N. Connell E, et al. Among authors: lesage c. Oncologist. 2024 May 18:oyae085. doi: 10.1093/oncolo/oyae085. Online ahead of print. Oncologist. 2024. PMID: 38761384 Free article.
68 results